Compare TLYS & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLYS | CELU |
|---|---|---|
| Founded | 1982 | 2016 |
| Country | United States | United States |
| Employees | N/A | 123 |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.3M | 35.2M |
| IPO Year | 2011 | N/A |
| Metric | TLYS | CELU |
|---|---|---|
| Price | $4.52 | $0.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.00 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 425.2K | 30.6K |
| Earning Date | 06-03-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.34 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.66 | N/A |
| Revenue Next Year | $1.74 | $76.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $0.93 |
| 52 Week High | $5.54 | $4.35 |
| Indicator | TLYS | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 55.97 | 33.12 |
| Support Level | $3.67 | N/A |
| Resistance Level | $5.54 | $1.46 |
| Average True Range (ATR) | 0.34 | 0.09 |
| MACD | -0.14 | -0.03 |
| Stochastic Oscillator | 44.12 | 24.31 |
Tilly's Inc works as a specialty retailer of casual apparel, footwear, and accessories for young men, young women, boys, and girls. It offers an unparalleled selection of relevant brands, styles, colors, sizes, and price points. It delivers branded fashion, and core styles for tops, outerwear, bottoms, and dresses. It also provides backpacks, hats, sunglasses, headphones, handbags, watches, and jewelry. It markets its products under the brand names of Vans, RVCA, Adidas, Nike SB, and Hurley among others. It operates its stores in malls, lifestyle centers, power centers, community centers, outlet centers, street-front locations, and also through e-commerce.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.